Crescom Co., Ltd. (CEO Jae-jun Lee), specialized in artificial intelligence analysis solutions for musculoskeletal medical data, announced on the 2nd that it was finally selected for the ‘AI convergence medical image medical reading system construction project’ hosted by the Ministry of Science and ICT and the National IT Industry Promotion Agency. Crescom, Idot, and JLK companies were finally selected for this project.
Crescom formed a consortium with Seoul National University Boramae Hospital, Seoul National University Bundang Hospital, and Korea University Anam Hospital to develop an artificial intelligence (AI) solution for knee arthritis diagnosis and screening for three years. The developed solution is used to support diagnosis in medical settings and review by the Health Insurance Review and Assessment Service (HIRA) in relation to degenerative knee arthritis.
As a company selected for this project, Crescom demonstrated its AI solution by attending the opening ceremony of the ‘Artificial Intelligence Convergence (AI+X) Project Medical Data Utilization Demonstration Lab’ held at the headquarters of the Health Insurance Review and Assessment Service in Wonju, Gangwon-do on the 28th of last month. At this event, Prime Minister Kim Boo-gyeom, Lee Kwang-jae, National Assembly member Song Ki-heon, and key officials from the Ministry of Science and ICT, Ministry of Health and Welfare, Ministry of Food and Drug Safety, Health Insurance Review and Assessment Service, and National IT Industry Promotion Agency (NIPA) attended and experienced solution demonstrations by participating companies. We communicated with businesspeople.
Cresscom’s patented technology complements the shortcomings of the existing bone age reading methods, GP and TW3, and integrates only the strengths of the hybrid growth plate examination artificial intelligence solution ‘MediAI-BA’ and the artificial intelligence fracture detection solution ‘MediAI-FX’. The demonstration demonstrated that it can help with timely, rapid and accurate readings in medical settings.
‘MediAI-BA’ was confirmed to be useful in the medical field in clinical trials for approval by the Ministry of Food and Drug Safety, and is currently helping more than 100 hospitals in Korea analyze growth plate bone age in children. ‘MediAI-FX’ is capable of detecting scaphoid fractures, which are difficult to detect but can cause serious aftereffects if left untreated, and is currently in the final stage of clinical trials.
Cresscom CEO Lee Jae-jun said, “Based on the support of the Ministry of Science and ICT, the National IT Industry Promotion Agency, and the Health Insurance Review and Assessment Service, we aim to help in the medical field and medical review, and advance into the global market so that it can be widely used not only in Korea but also in overseas markets. “I will also actively do my best.”
Source: Pangyo Techno Valley Official Newsroom
→ Go to ‘Asia Innovation Hub Pangyo Techno Valley 2021’ news